Ongoing Clinical Trials for AMD at Casey Eye Institute
Comparison of Age-Related Macular Degeneration Treatment Trials (CATT)
Purpose: To evaluate the safety and efficacy of Lucentis and Avastin for treatment of wet AMD. Study patients were followed for two years and received injections of Lucentis or Avastin every month on a fixed schedule or as needed. The two-year results, published in May 2012, found that the two drugs were similarly effective.
Contact: Ann Lundquist, 503 494-6364
Genetics of Age-Related Macular Degeneration Study
Purpose: To find genetic mechanisms associated with age-related macular degeneration. Large families with at least four living affected members are being recruited and followed. Volunteers receive eye photography and DNA analysis at no cost. No travel is required.
Contact: Jennifer Maykoski, 503 494-3064
Age-Related Eye Disease Study (AREDS2)
Purpose: To evaluate the effects of lutein and zeaxanthin and omega-3 fatty acids on people at risk of progressing to advanced AMD and/or suffering moderate vision loss. The study is being carried out at the Devers Eye Institute in Portland, which is one of the clinical centers sponsored by the National Eye Institute (NEI). Enrollment is completed and participants are being followed.
Contact: Devers Eye Institute, 503 413-8356.
Combination Ranibizumab and Pazopanib for Neovascular (Wet) AMD
Purpose: To demonstrate whether pazopanib eye drops are a safe and effective treatment for wet AMD in subjects whose disease is currently managed with anti-VEGF therapy. The study is evaluating whether daily doses of pazopanib eye drops can maintain or possibly improve vision, while reducing the continued need for anti-VEGF injections. Enrollment is closed and patients are being followed.
Contact: Mitchell Schain, 503 494-3115 or Shelley Hanel, 503-494-1986
